Ligand Pharmaceuticals unterstreicht Resilienz im Biotech-Sektor
Ligand Pharmaceuticals ist ein US-Biopharmaunternehmen mit Sitz in Jupiter (Florida), das sich auf ein Lizenz- und Royalty-Modell spezialisiert hat: Anstatt…
138,000€
1,47%
Echtzeit-Aktienkurs Ligand Pharmaceuticals
Bid:
Ask:
Nachrichten zur Ligand Pharmaceuticals Aktie
Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward
…
Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies
…
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ:…
invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology
VIENNA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies…
Ligand Pharmaceuticals Incorporated 2024 Q2 - Results - Earnings Call Presentation
…
Ligand Pharmaceuticals reports mixed Q2 results; reaffirms FY24 outlook
…
Ligand Pharmaceuticals: Solid Performer Performing Solidly
…
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.…
Ligand Pharmaceuticals Incorporated 2024 Q1 - Results - Earnings Call Presentation
…
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
Ligand Pharmaceuticals (LGND) reports encouraging fourth-quarter results as earnings and sales beat estimates. Management reiterates the 2024 financial outlook.…